= Emerging. More than 5 years before clinical availability. |
= Expected to be clinically available in 1 to 4 years. |
= Clinically available now. |
Topic: Practical Training
Authors: Timothy S. Collier
|
||
Short Abstract The development of protein mass spectrometric assays for use in the clinical laboratory presents unique workflow challenges. Specific pre-analytical steps, such as enzymatic proteolytic digestion, are often required to generate peptides amenable to mass spectrometric analysis. This process requires close attention during and after assay development to ensure reproducible and accurate clinical analysis. |
||
Long Abstract Introduction The deployment of proteomic assays in the clinical laboratory is in its infancy compared to more traditional immunological-based platforms. Given the wide range of physical and chemical properties of proteins, methods for their analysis can present unique challenges in their development and routine use. Many assays utilize enzymatic digestion workflows to reduce proteins to surrogate peptides that are more amenably measured in a typical LC-MS workflow. . This process requires close attention during and after assay development to ensure reproducible and accurate clinical analysis. The first part of this practical training session will present a typical digestion workflow and offer insights into pre-digestion sample treatment strategies, enzyme selection, and optimization of digestion conditions. The second and third parts of this practical training session will discuss strategies for assessing reagent quality and assay performance, both with respect to the development process and to monitoring assay performance in an operations environment.
Methods Results Conclusions & Discussion |
||
References & Acknowledgements:
|
Description | Y/N | Source |
Grants | no | |
Salary | yes | Quest Diagnostics - Cleveland HeartLab |
Board Member | no | |
Stock | yes | Quest Diagnostics |
Expenses | no |
IP Royalty: no
Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |